SHILPAMED Shilpa Medicare Q1 FY26 results (Apr–Jun 2025) and concall
Shilpa Medicare reported a strong Q1 FY26 with record EBITDA and significant gross margin expansion, driven by growth in API and Biologics segments. The company made progress in its oncology and non-oncology API pipeline, launched its first NCE (Nor-Ursodeoxycholic acid) in India, and advanced its Biologics programs. Capital allocation included ₹70 crores in capex for a fermentation plant and a proposed 1:1 bonus issue, while net debt stood at ₹550 crores.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 130 | 125 | 126 | 92 |
| EBITDA | 43 | 22 | 38 | 17 |
| Net profit | 30 | 16 | -6 | 21 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
